Abpro Holdings (ABPO) Other Operating Expenses (2022 - 2023)
Abpro Holdings' (ABPO) quarterly Other Operating Expenses came in at $10.6 million in Q4 2023, up 1699.87% YoY from $588645.0 in Q4 2022, and up 3260.81% on a QoQ basis from $315247.0 in Q3 2023.
Abpro Holdings (ABPO) Other Operating Expenses (2022 - 2023) Analysis & Trends
Abpro Holdings (ABPO) has 2 years of Other Operating Expenses data on file, last reported at $10.6 million in Q4 2023.
- Quarterly Other Operating Expenses rose 1699.87% year-over-year to $10.6 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $10.6 million (up 469.07% YoY) and the FY2022 annual result came in at $2.0 million, up 110686.95% from the prior year.
- Other Operating Expenses advanced to $10.6 million in Q4 2023, from $315247.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $10.6 million in Q4 2023 to a low of $315247.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 315,247.00 |
| Jun 30, 2023 | 420,341.00 |
| Mar 31, 2023 | 537,558.00 |
| Dec 31, 2022 | 588,645.00 |
| Sep 30, 2022 | 533,796.00 |
| Jun 30, 2022 | 434,432.00 |
| Mar 31, 2022 | 493,537.00 |